期刊文献+

β受体拮抗剂联合替莫唑胺治疗转移性副神经节瘤病例报告分析 被引量:1

Case report analysis ofβ-receptor antagonist combined with temozolomide in the treatment of metastatic paraganglioma
下载PDF
导出
摘要 目的探讨转移性副神经节瘤的特点,以此提高临床对转移性副神经节瘤的临床认识和诊治水平。方法回顾性分析1例转移性副神经节瘤的临床资料及诊治经过,复习文献,对转移性副神经节瘤的特点进行讨论。结果1例67岁男性转移性副神经节瘤患者,反复血压波动大且贫血,二线经过β受体拮抗剂联合替莫唑胺治疗患者肿瘤缩小,血压恢复平稳,贫血改善,获得>7个月的无进展生存。结论运用β受体拮抗剂联合替莫唑胺成功治疗1例转移性副神经节瘤。 Objective To discuss the characteristics of metastatic paraganglioma,so as to improve the clinical understanding and diagnosis and treatment of metastatic paraganglioma.Methods The clinical data,diagnosis and treatment of 1 case of metastatic paraganglioma were analyzed retrospectively.The characteristics of metastatic paraganglioma were discussed by reviewing the literature.Results A 67-year-old male patient with metastatic paraganglioma had recurrent blood pressure fluctuation and anemiaβ.After a second-line therapy ofβ-receptor antagonist and temozolomide,patient has shrank tumor,stable blood pressure,improved anemia,and the patient achieves progression-free survival for>7 months.
作者 吕仙梅 方敏 施勋 郭秋生 LYU Xian-mei;FANG Min;SHI Xun(Department of Onology,People’s Hospital of Kecheng District,Quzhou 324000,China)
出处 《中国实用医药》 2021年第23期181-183,共3页 China Practical Medicine
关键词 转移性副神经节瘤 替莫唑胺 化疗 Β受体拮抗剂 Metastatic paraganglioma Temozolomide Chemotherapy β-receptor antagonist
  • 相关文献

参考文献1

二级参考文献18

  • 1祝宇,王卫庆,沈永倩,吴瑜璇,张翀宇,芮文斌,周文龙,孙福康,刘定益,邵远,沈周俊,毕宇芳,苏颋为,姜蕾,宁光.嗜铬细胞瘤术前的高血压控制与术中高容量血液稀释[J].临床泌尿外科杂志,2006,21(8):571-573. 被引量:3
  • 2曾正陪.肾上腺髓质疾病[A].史轶蘩主编.协和内分泌和代谢学:第1版[C].北京:科学出版社,1999.1222-1244.
  • 3曾正陪.嗜铬细胞瘤.见:陈家伦,主编.临床内分泌学[M].上海:上海科学技术出版社,2011.63744.
  • 4Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2014,99 (6) : 1915-1942. DOI: 10. 1210/ jc. 2014-1498.
  • 5Shuch B, Ricketts C J, Metwalli AR, et al. The genetic basis of pheochromocytoma and paraganglioma: implications for management [ J ]. Urology, 2014, 83 ( 6 ) : 1225-1232. DOI: 10. 1016/j. urology. 2014.01. 007.
  • 6Dahia PL. Pheochromocytoma and paragang|ioma pathogenesis: learning from genetic heterogeneity [ J ]. Nat Rev Cancer, 2014, 14 (2) :108-119. DOI: 10. 1038/nrc3648.
  • 7D6nes J, Swords F, Rattenberry E, et al. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort [ J ]. J Clin Endocrinol Metab, 2015, 100 (3) : E531-541. DOI: 10. 1210/jc. 2014-3399.
  • 8Welander J, Andreasson A, Juhlin CC, et al. Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma [ J ]. J Clin Endocrinol Metab, 2014,99(7) :E1352-1360. DOI: 10. 1210/jc. 2013-4375.
  • 9Bravo EL, Gifford JR. Diagnosis. In: Manger WM, Gifford RW (eds). Clinical and Experimental Pheochromocytoma [ M ]. 2nd ed. Cambridge Mass: Blackwell Science, 1996. 205-332.
  • 10van Hulsteijn LT, Niemeijer ND, Dekkers OM, et at. ( 131 ) I-MIBG therapy for malignant paraganglioma and phaeochmmocytoma : systematic review and meta-analysis [ J ]. Clin Endocrinol ( Oxf ), 2014,80(4) :487-501. DOI: 10. llll/cen. 12341.

共引文献115

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部